Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer

This publication has 123 references indexed in Scilit:

• The Cancer Genome Atlas Pan-Cancer analysis project
  Nature Genetics, 2013
• A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
  Investigational New Drugs, 2012
• A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
  Investigational New Drugs, 2012
• Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
  Investigational New Drugs, 2012
• A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
  Breast Cancer Research and Treatment, 2012
• Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer
  Clinical Colorectal Cancer, 2011
• Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
  The Lancet Oncology, 2011
• Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
  JAMA, 2010
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
  The Lancet Oncology, 2010
• Colorectal cancer
  The Lancet, 2010